Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02470715 · ClinicalTrials.gov registry record
Identifying Molecular Drivers of Cancer
A clinical trial, sponsored by Avera McKennan Hospital & University Health Center.
- Completed
- Registry status
- 579
- Enrollment target
NCT02470715: Completed study, sponsored by Avera McKennan Hospital & University Health Center.
NCT02470715 is a clinical trial that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 579 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02470715 has completed, sponsored by Avera McKennan Hospital & University Health Center.
- COMPLETED
- Registry status
- 579 participants
- Enrollment target
Study Summary
The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.
Primary Outcome
To determine genetic changes associated with the development and growth of human disease. This should lead to better ways to detect, prevent, and treat a wide variety of human health conditions, including cancer.
Interventions
- GENETIC Molecular profile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-05-22 |
What the finished NCT02470715 record still lists
NCT02470715 is an observational study that tracks outcomes without assigning an intervention. The registered 579 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Molecular profile is the first listed.
NCT02470715 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02470715 about?
NCT02470715 is a clinical study titled "Identifying Molecular Drivers of Cancer". The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.
What is the current status of trial NCT02470715?
This trial is currently completed. The enrollment target is 579 participants. The study started on 2014-04. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02470715?
The interventions under investigation include: Molecular profile (GENETIC).
Who is sponsoring clinical trial NCT02470715?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia